Product News from the May 6th MM&M News Brief

Share this article:

PRODUCT NEWS
The FDA yesterday approved GlaxoSmithKline's Requip, a treatment for restless legs syndrome, a condition that can disrupt sleep and daily activities.

Amylin announced FDA approval of Byetta for treatment of patients with Type 2 diabetes. Byetta will be available by June 1, 2006, Amylin said.

The FDA has approved GlaxoSmithKline's Boostrix, the first combination vaccine that provides a booster immunization against pertussis (whooping cough) in combination with tetanus and diphtheria for adolescents.

Share this article:

Email Newsletters

More in Business Briefs

Illumina inks deal with J&J, AstraZeneca, Sanofi

The goal is to develop companion diagnostics to match patients with cancer treatments.

Abbott deal highlights inversion inaction

Political furor over the recent spate of tax inversions is having little influence on how the government chooses its partners.

Allergan reported to seek out Salix deal

The Wall Street Journal says the deal would add "another layer of intrigue" to the Allergan-Valeant hostilities.